Observing clinical outcomes in patients with cardiovascular diseases
Clinical Outcomes of Cardiovascular Disease: a Prospective Cohort Study
This study looks at how people with heart diseases, like coronary heart disease and heart failure, do over time to see what factors affect their health and risk of serious events.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30000 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Xinjiang Medical University Academic / other |
| Locations | 1 site (Ürümqi, Xinjiang) |
| Trial ID | NCT06459934 on ClinicalTrials.gov |
What this trial studies
This observational study is a prospective, single center cohort analysis that registers the clinical characteristics and outcomes of patients suffering from various cardiovascular diseases, including coronary heart disease, heart failure, and hypertension. Patients will undergo multiple examinations at baseline and at one year or longer to evaluate the incidence of major cardiovascular and cerebrovascular events, heart failure readmissions, and mortality. The study aims to identify influencing factors on these outcomes over time.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 to 80 with diagnosed coronary heart disease, hypertension, heart failure, or cardiomyopathy.
Not a fit: Patients under 18 or over 80 years old, those with malignant tumors, liver dysfunction, or renal insufficiency may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide valuable insights into the long-term outcomes and management of patients with cardiovascular diseases.
How similar studies have performed: Other studies have shown success in observing clinical outcomes in cardiovascular diseases, making this approach well-established.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Coronary heart disease According to coronary angiography and coronary CTA, at least one coronary artery has a degree of stenosis greater than 50%. 2. Hypertension Hypertension is defined as office systolic blood pressure is ≥ 140mmHg and/or the diastolic blood pressure is ≥ 90mmHg without the use of antihypertensive drugs. 3. Heart failure There is a clear history of organic heart disease, clinical symptoms and signs of heart failure, and objective evidence of heart failure. 4. Cardiomyopathy Including defined dilated cardiomyopathy, hypertrophic cardiomyopathy, restrictive cardiomyopathy, etc. 5. Able to sign informed consent form. Exclusion Criteria: 1. Age\<18 years old, or\>80 years old. 2. Patients with various malignant tumors. 3. Liver dysfunction (defined as ALT or total bilirubin greater than three times the upper normal limit). 4. Renal insufficiency (defined as blood creatinine exceeding 1.5 times the upper normal limit). 5. Those who have participated in other clinical studies within the past three months. 6. Individuals without legal capacity or with limited legal capacity. 7. Any situation where the researcher deems it unsuitable to participate in the clinical study.
Where this trial is running
Ürümqi, Xinjiang
- The First Affiliated Hospital of Xinjiang Medicial University — Ürümqi, Xinjiang, China (Recruiting)
Study contacts
- Principal investigator: Xiang Xie, Prof — Xinjiang Medical University
- Study coordinator: Ying-Ying Zheng, PhD
- Email: zhengying527@163.com
- Phone: +8615214804944
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.